- In April 2024, Adherium has unveiled a new FDA-cleared Smart inhaler compatible with the AirSupra and Breztri inhalation devices. This innovative device is designed to enhance the management of chronic respiratory diseases such as asthma and COPD by providing real-time tracking and personalized data. It will enable patients and healthcare providers to monitor medication adherence and inhaler usage through a connected app, helping to optimize treatment plans. The Smartinhaler aims to improve patient outcomes by fostering better disease control, reducing exacerbations, and empowering individuals to take proactive steps in managing their respiratory conditions
- In October 2021, BreatheSuite announced FDA clearance for its device that transforms standard inhalers into smart inhalers. This innovative device enables real-time tracking of inhaler usage through a connected app, providing patients and healthcare providers with valuable data on medication adherence and frequency of use. By enhancing monitoring and offering actionable insights, the device aims to improve patient compliance and management of respiratory diseases such as asthma and COPD. It will ultimately support better disease control, reduce the risk of exacerbations, and help optimize treatment outcomes for individuals with chronic respiratory conditions
